Pro Vise Management Group, LLC Novo Nordisk A S Transaction History

Pro Vise Management Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$119.07 - $145.42 $1,905 - $2,326	16 Added 0.44%	3,647 $434,000
Q2 2024 Aug 12, 2024	BUY	$122.71 - $146.91 $1,104 - $1,322	9 Added 0.25%	3,631 $518,000
Q4 2023 Feb 09, 2024	BUY	$87.78 - $105.45 $2,282 - $2,741	26 Added 0.72%	3,622 $374,000
Q3 2023 Nov 08, 2023	BUY	$90.94 - $199.54 $163,510 - $358,772	1,798 Added 100.0%	3,596 $327,000
Q4 2022 Feb 09, 2023	BUY	$102.55 - $135.33 $184,384 - $243,323	1,798 New	1,798 $243,000
Q4 2021 Jan 18, 2022	BUY	$95.88 - $117.08 $172,392 - $210,509	1,798 New	1,798 $201,000

1,869

336M

11.9M

10.6M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $131B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Pro Vise Management Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Vise Management Group, LLC with notifications on news.